Retrospective analysis of impact of automated insulin delivery technology on acute care utilisation from 2019 to 2021
Authors' conclusion
Use of AID systems among PwT1D was associated with lower odds of IP and ED utilisation and lower costs in the follow-up period compared to MDI.
Study context
- Population
- People with T1D treated with MDI or newly starting automated insulin delivery (AID), identified 15 January 2020–31 December 2020, continuously enrolled ≥12 months pre- and post-index
- Participants
- 7,264 vs 27,973
- Exposure
- AID system vs MDI
- AIDn = 7,264
- MDIn = 27,973reference
- Outcome
- Odds and costs of acute care utilisation (IP admission and ED visit)
- Follow-up
- 12 months
Methodological detailsobservational, electronic health record (EHR) and administrative claims data, multivariable adjusted, Data from 15 January 2019 through 31 December 2021
- Observational
- EHR and administrative claims data
- Multivariable adjusted
- Data from 15 January 2019 through 31 December 2021
Main finding
As reported in the abstract
Adjusted odds of inpatient (IP) admission
0.70
95% CI 0.63–0.77
AID
Adjusted odds of emergency department (ED) visit
0.76
95% CI 0.70–0.82
AID
Observational data: associations, not effects.
Further findings
Average $
| Outcome | AID | MDI | P value |
|---|---|---|---|
| Average all-cause IP admission costs · 12 monthsAdjusted for pre-index characteristics | 3054 | 4701 | P < 0.001 |
| Average ED visit costs · 12 monthsAdjusted for pre-index characteristics | 1230 | 1793 | P < 0.001 |
Original publication
Retrospective analysis of impact of automated insulin delivery technology on acute care utilisation from 2019 to 2021. Diabet Med. Published 4 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →